|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | University of Medicine and Dentistry New Jersey |
|---|---|
| Information provided by: | University of Medicine and Dentistry New Jersey |
| ClinicalTrials.gov Identifier: | NCT00245830 |
Purpose
The long-term goals of this proposal are to develop clinical protocols of donor preconditioning to improve liver graft function and ameliorate complications of poor graft function after liver transplantation. Achievement of these objectives would improve liver recipient outcomes, increase utilization of livers and alleviate the current critical shortage of livers for transplantation. More stringent liver donor selection intended to decrease the complications of poor graft function conflicts directly with efforts to maximize the use of donor livers. Ischemic preconditioning (IPC) of liver attenuates hepatic ischemia reperfusion injury (IRI) in animals. Preliminary data show hepatic IPC effectively decreases IRI following hepatic resection in humans.
The specific aims of this project are: AIM 1: To test the hypothesis that 10 minutes of hepatic ischemic preconditioning in deceased donors would improve liver graft function and decrease injury in the early post transplant period. AIM 2: To test the hypothesis that ischemic preconditioning of deceased donor livers would decrease systemic inflammatory response in liver recipients in the early post transplant period. AIM 3: To examine whether ischemic preconditioning of deceased donor livers decreases early post transplant pulmonary edema and acute rejection and shortens hospital stay.
| Condition | Intervention | Phase |
|---|---|---|
|
Liver Cirrhosis Liver Transplantation |
Procedure: Ischemic Preconditioning |
Phase II Phase III |
| Study Type: | Interventional |
| Study Design: | Treatment, Randomized, Single Blind, Active Control, Parallel Assignment, Efficacy Study |
| Official Title: | Ischemic Preconditioning of Liver in Cadaver Donors |
| Estimated Enrollment: | 100 |
| Study Start Date: | October 2003 |
| Study Completion Date: | March 2007 |
Hide Detailed DescriptionSpecific Aims
To test the hypothesis that 10 minutes of hepatic ischemic preconditioning in deceased donors would improve liver graft function and decrease injury in the early post transplant period.
To accomplish this aim, we will compare International Normalized Ratios of prothrombin time (INR/PT) and serum aspartate (AST) and alanine aminotransferase (ALT) and total bilirubin (TB) levels immediately post transplant and on day 1, 3, 7, 14 and 30 and injury score of reperfusion liver biopsies in recipients of livers from IPC and No IPC donors.
To test the hypothesis that ischemic preconditioning of deceased donor livers would decrease the systemic inflammatory response in liver recipients in the early post transplant period.
To accomplish this aim, we will compare plasma levels of cytokines tumor necrosis factor- (TNF-), interleukins-6, 8 and 10 (IL-6, 8 and 10) and soluble L-selectin, expression levels of adhesion molecules (CD11/CD18 and L-selectin) and oxidative burst of neutrophils, platelet P-selectin and platelet-neutrophil complexes (PNC) in the peripheral blood 3, 12, 24 and 48 hours following reperfusion in recipients of livers from IPC and No IPC donors.
To accomplish this aim, we will compare interstitial and alveolar edema in chest radiographs done after transplant and on post operative days 1, 2 and 3; biopsy confirmed acute rejection within 30 days post transplant, and number of days to discharge after transplantation in recipients of livers from IPC and No IPC donors.
Research Design A prospective, randomized, and single masked (liver recipients) study will be conducted in one liver transplant center over a period of two years. Deceased liver donors will be randomized in equal proportions to one of two organ recovery procedures: 1). IPC or 2). No IPC. Allocation will be stratified by age < 50 or age >= 50 to facilitate examination of the effects of age on IPC. As the trial will enroll donors over a two-year period, treatment assignments will be balanced over blocks of length 12, 16 and 20, where the length will be selected at random, to control for time varying factors. Recovered livers are transplanted into recipients > 18 years of age. All other aspects of donor management, organ recovery and preservation, recipient selection, graft implantation and post transplant management including immunosuppression will be according to standard practice.
II. Research Methods
Liver Recovery and IPC: Donors are positioned supine, mechanically ventilated and administered 100% oxygen and a muscle relaxant. The abdomen and chest are opened in the midline. Briefly, round and falciform ligaments are divided and the gallbladder is incised and irrigated. The gastroduodenal artery is ligated and junction of splenic and superior mesenteric veins or, when pancreas is procured, the inferior mesenteric vein is prepared for canulation. The supraceliac aorta is exposed just below the diaphragm. The infrarenal abdominal aorta is isolated for canulation. No mobilization of the kidneys is performed before organ perfusion. Thoracic organs are mobilized either simultaneously or before mobilization of abdominal organs. Five hundred units/kg of heparin is given intravenously and ascending thoracic and infrarenal abdominal aorta are canulated. Another canula is inserted either into splenic vein or inferior mesenteric vein. The supraceliac abdominal aorta is clamped and the inferior vena cava is vented in the pericardium. UW solution (40C) is infused into abdominal aorta and portal vein (2 liters each). The abdominal cavity is packed with ice slush. Following completion of organ perfusion heart, lungs, liver and pancreas and kidneys are removed in sequence. Livers are placed in plastic bags containing a liter of UW solution (40C) and packed in ice until the time of transplantation.
Ischemic preconditioning is performed soon after opening the abdomen by clamping the hepatic hilum with a vascular clamp for five minutes, which is repeated again after five minutes of reperfusion. During IPC the peritoneal cavity is inspected for bleeding, congestion and edema of the pancreas and small intestine.
Eligibility| Ages Eligible for Study: | 18 Years to 80 Years |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Deceased donor livers allocated to adult (> 18 years of age) recipients at the research site.
Exclusion Criteria:
Contacts and Locations| United States, New Jersey | |
| University Hospital | |
| Newark, New Jersey, United States, 07101 | |
| Principal Investigator: | Baburao Koneru, M.D. | UMDNJ-New Jersey Medical School |
More Information
| Study ID Numbers: | 0120010348 |
| Study First Received: | October 26, 2005 |
| Last Updated: | April 27, 2007 |
| ClinicalTrials.gov Identifier: | NCT00245830 History of Changes |
| Health Authority: | United States: Institutional Review Board |
|
Ischemia/reperfusion of the liver Ischemic Preconditioning Cadaver organ donor |
|
Liver Diseases Death Cadaver Digestive System Diseases |
Pathologic Processes Fibrosis Liver Cirrhosis |